189 related articles for article (PubMed ID: 29187439)
1. Expression of FAS-L Differs from Primary to Relapsed Low-grade Gliomas and Predicts Progression-free Survival.
Werner JM; Kuhl S; Stavrinou P; Röhn G; Krischek B; Blau T; Goldbrunner R; Timmer M
Anticancer Res; 2017 Dec; 37(12):6639-6648. PubMed ID: 29187439
[TBL] [Abstract][Full Text] [Related]
2. Glioma-associated stem cells: a novel class of tumor-supporting cells able to predict prognosis of human low-grade gliomas.
Bourkoula E; Mangoni D; Ius T; Pucer A; Isola M; Musiello D; Marzinotto S; Toffoletto B; Sorrentino M; Palma A; Caponnetto F; Gregoraci G; Vindigni M; Pizzolitto S; Falconieri G; De Maglio G; Pecile V; Ruaro ME; Gri G; Parisse P; Casalis L; Scoles G; Skrap M; Beltrami CA; Beltrami AP; Cesselli D
Stem Cells; 2014 May; 32(5):1239-53. PubMed ID: 24375787
[TBL] [Abstract][Full Text] [Related]
3. Corpus callosum involvement and postoperative outcomes of patients with gliomas.
Chen KT; Wu TW; Chuang CC; Hsu YH; Hsu PW; Huang YC; Lin TK; Chang CN; Lee ST; Wu CT; Tseng CK; Wang CC; Pai PC; Wei KC; Chen PY
J Neurooncol; 2015 Sep; 124(2):207-14. PubMed ID: 26033546
[TBL] [Abstract][Full Text] [Related]
4. In vitro neurosphere formation correlates with poor survival in glioma.
C Jayakrishnan P; H Venkat E; M Ramachandran G; K Kesavapisharady K; N Nair S; Bharathan B; Radhakrishnan N; Gopala S
IUBMB Life; 2019 Feb; 71(2):244-253. PubMed ID: 30393962
[TBL] [Abstract][Full Text] [Related]
5. ACTC1 as an invasion and prognosis marker in glioma.
Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
7. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
8. Death Receptor 6 as a Prognostic Marker in Low-grade Glioma.
Stegmann SK; Kuhl S; Im NG; Diem-Dinh DT; Goertz L; Goldbrunner R; Timmer M
Anticancer Res; 2022 Mar; 42(3):1237-1245. PubMed ID: 35220214
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma.
Jeong SY; Lim SM
Nucl Med Biol; 2012 Oct; 39(7):977-81. PubMed ID: 22483845
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma.
Pang C; Guan Y; Zhao K; Chen L; Bao Y; Cui R; Li G; Wang Y
Int J Clin Exp Pathol; 2015; 8(5):4943-52. PubMed ID: 26191187
[TBL] [Abstract][Full Text] [Related]
11. ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas.
Fan X; Wang Y; Zhang C; Liu L; Yang S; Wang Y; Liu X; Qian Z; Fang S; Qiao H; Jiang T
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27571068
[TBL] [Abstract][Full Text] [Related]
12. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
13. Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945.
Eisenstat DD; Pollack IF; Demers A; Sapp MV; Lambert P; Weisfeld-Adams JD; Burger PC; Gilles F; Davis RL; Packer R; Boyett JM; Finlay JL
J Neurooncol; 2015 Feb; 121(3):573-81. PubMed ID: 25431150
[TBL] [Abstract][Full Text] [Related]
14. Expression levels of Fas/Fas-L mRNA in human brain glioma stem cells.
Tao J; Qiu B; Zhang D; Wang Y
Mol Med Rep; 2012 May; 5(5):1202-6. PubMed ID: 22344564
[TBL] [Abstract][Full Text] [Related]
15. Expression of YAP1 and pSTAT3-S727 and their prognostic value in glioma.
Sang W; Xue J; Su LP; Gulinar A; Wang Q; Zhai YY; Hu YR; Gao HX; Li X; Li QX; Zhang W
J Clin Pathol; 2021 Aug; 74(8):513-521. PubMed ID: 33020176
[TBL] [Abstract][Full Text] [Related]
16. High bone sialoprotein (BSP) expression correlates with increased tumor grade and predicts a poorer prognosis of high-grade glioma patients.
Xu T; Qin R; Zhou J; Yan Y; Lu Y; Zhang X; Fu D; Lv Z; Li W; Xia C; Hu G; Ding X; Chen J
PLoS One; 2012; 7(10):e48415. PubMed ID: 23119009
[TBL] [Abstract][Full Text] [Related]
17. Human leukocyte antigen-G overexpression predicts poor clinical outcomes in low-grade gliomas.
Fan X; Wang Y; Zhang C; Liu X; Qian Z; Jiang T
J Neuroimmunol; 2016 May; 294():27-31. PubMed ID: 27138095
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma.
Gressot LV; Doucette T; Yang Y; Fuller GN; Manyam G; Rao A; Latha K; Rao G
Oncotarget; 2017 Feb; 8(8):12695-12704. PubMed ID: 27074575
[TBL] [Abstract][Full Text] [Related]
19. Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.
Koo T; Lim DH; Seol HJ; Dho YS; Kim IH; Chang JH; Lee J; Jung TY; Gwak HS; Cho KH; Hong CK; Lee IJ; Kim E; Kim JH; Hong YK; Jang HS; Kim CY; Kim IA; Kim SH; Kim YI; Kim EY; Kim WC; Hong S
J Neurooncol; 2018 Nov; 140(2):445-455. PubMed ID: 30097825
[TBL] [Abstract][Full Text] [Related]
20. Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma.
Su X; Li H; Chen S; Qin C
Technol Cancer Res Treat; 2021; 20():15330338211010143. PubMed ID: 33896271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
